Open AccessThe efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
Author(s) -
Simin Fan,
Xiaoyan Shi,
Jia Yao,
Min Zhong,
Peimin Feng
Publication year - 2020
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.6392/2019
Subject(s) - medicine , gastroenterology , fatty liver , exenatide , cochrane library , meta analysis , randomized controlled trial , adiponectin , confidence interval , subgroup analysis , aspartate transaminase , alanine transaminase , metabolic syndrome , endocrinology , type 2 diabetes , disease , diabetes mellitus , obesity , insulin resistance , alkaline phosphatase , biochemistry , enzyme , chemistry
non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of metabolic syndrome and is highly prevalent all over the world. New drugs are urgently needed for the treatment of NAFLD. The aim of this meta-analysis was to assess the efficacy of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in patients with NAFLD.